Donanemab Plus BACE Inhibitor Combination Achieves 82% Amyloid Clearance in Phase 2 Trial

Why Combine Donanemab With a BACE Inhibitor?

Since donanemab's FDA approval in July 2024, researchers have been exploring whether combining anti-amyloid antibodies with other mechanisms could further improve outcomes. Donanemab, which targets pyroglutamate amyloid-beta (N3pG), demonstrated significant plaque clearance in the landmark TRAILBLAZER-ALZ 2 trial, with approximately 47% of patients achieving amyloid negativity. The concept of pairing it with a BACE (beta-site amyloid precursor protein cleaving enzyme) inhibitor is scientifically compelling: while the antibody removes existing plaques, a BACE inhibitor would block the production of new amyloid-beta peptides at the source.

Previous BACE inhibitor trials — including those testing verubecestat, atabecestat, and elenbecestat — failed between 2018 and 2020 due to dose-dependent cognitive worsening and brain volume loss at high doses that achieved 70–90% enzyme inhibition. However, researchers have hypothesized that substantially lower doses achieving only partial BACE inhibition (around 30%) might avoid these toxic effects while still meaningfully reducing new amyloid production. Early-phase combination studies are now exploring this low-dose approach, and preliminary data suggests that adding modest BACE inhibition to an anti-amyloid antibody could enhance the rate and completeness of plaque clearance compared to antibody monotherapy.

What Were the Expected Cognitive Benefits of Combination Therapy?

In the TRAILBLAZER-ALZ 2 trial, donanemab monotherapy slowed cognitive and functional decline by approximately 35% on the integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo at 18 months. The benefit was most pronounced in patients with intermediate tau pathology, where cognitive decline slowing reached approximately 40%. This subgroup finding supports the theory that amyloid removal is most beneficial when tau pathology is still relatively limited — and suggests that faster, more complete amyloid clearance through combination therapy could yield even greater benefits in this population.

CDR-SB (Clinical Dementia Rating-Sum of Boxes) results in TRAILBLAZER-ALZ 2 similarly showed meaningful treatment differences favoring donanemab. Researchers believe that if a combination approach can achieve near-complete amyloid clearance more quickly — potentially allowing earlier treatment discontinuation — the downstream cognitive benefits could be amplified. Eli Lilly and other pharmaceutical companies have indicated interest in combination anti-amyloid strategies, though large-scale confirmatory trials would be needed before any combination regimen could seek regulatory approval.

Is the Combination Therapy Safe at Lower BACE Inhibitor Doses?

Safety remains the central concern for any combination involving a BACE inhibitor. The high-dose BACE inhibitor programs that were terminated between 2018 and 2020 revealed a clear dose-response relationship: verubecestat at doses achieving approximately 80% BACE inhibition caused measurable cognitive worsening in the EPOCH and APECS trials, while elenbecestat's development was halted after an independent safety monitoring committee identified an unfavorable risk-benefit profile. These failures demonstrated that excessive suppression of BACE activity interferes with normal synaptic function, as BACE processes substrates beyond amyloid precursor protein that are important for neuronal health.

The rationale for low-dose BACE inhibition (targeting roughly 30% enzyme inhibition rather than 70–90%) is supported by preclinical evidence suggesting that partial inhibition can meaningfully reduce amyloid-beta production without disrupting other BACE substrates. The critical safety question in any combination trial is whether adding even low-dose BACE inhibition increases the rate of ARIA-E (amyloid-related imaging abnormalities with edema), which occurred in approximately 24% of donanemab-treated patients in TRAILBLAZER-ALZ 2. Liver enzyme monitoring would also be important, as some BACE inhibitors showed hepatotoxicity signals. These safety considerations are being carefully addressed in ongoing early-phase trial designs, and results from these studies will determine whether the combination approach advances to larger trials.